Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Wearable Cardiac Biomarker Testing at the Point of Need

Ziel

Every year, an estimated 2 million EU emergency ambulance transports for chest pain reach hospital without a single troponin measurement — the biomarker needed to confirm or rule out myocardial infarction (heart attack). After discharge, a substantial proportion of patients who develop post-infarction heart failure are rehospitalised within 30 days, with no tool to monitor troponin at home. This gap persists because troponin circulates at concentrations orders of magnitude lower than glucose, the required biofluids cannot be accessed without invasive sampling, and no minimally invasive wearable for troponin has yet been clinically validated for pre-hospital or home use.
FIRST-SIGN addresses these barriers using advances from the ERC Starting Grant 2ND-CHANCE (Grant No. 101043119). The parent grant developed aptamer-based troponin detection across the clinically relevant range and hollow microneedle arrays for minimally invasive interstitial fluid (ISF) extraction through the skin. FIRST-SIGN integrates these into a wearable patch that samples ISF via microneedles, measures cardiac troponin I (cTnI) with an aptamer-functionalised electrode, and is designed to return results to a smartphone within 10–20 minutes without a blood draw or trained operator.
During ambulance transport, the patch could provide clinicians with an early signal of cardiac injury; after discharge, it aims to let patients detect silent re-infarction at home before it becomes an emergency. Because the quantitative relationship between ISF and blood troponin remains poorly characterised, establishing this correlation is a central objective. Over 18 months, FIRST-SIGN will (1) adapt the biosensor for wearable operation, (2) benchmark ISF-derived troponin against venous blood in cardiac patients across cohorts, (3) build and usability-test an integrated prototype, and (4) define the regulatory and commercialisation pathway. Success will position the device for CE marking and subsequent commercialisation in pre-hospital triage and post-discharge home cardiac monitoring.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

KOC UNIVERSITY
Netto-EU-Beitrag
€ 150 000,00
Adresse
RUMELI FENERI YOLU SARIYER
34450 Istanbul
Türkei
Region
İstanbul İstanbul İstanbul
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Begünstigte (1)